# Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

> **NCT03518112** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Philadelphia Chromosome Negative
- Recurrent B Acute Lymphoblastic Leukemia
- Refractory B Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** Blinatumomab
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **BIOLOGICAL:** Filgrastim
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Leucovorin Calcium
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **BIOLOGICAL:** Pegfilgrastim
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT03518112
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-18
- **Primary completion:** 2021-05-27
- **Final completion:** 2021-05-27
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Due to Competing Studies
- **Last updated:** 2022-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03518112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03518112, "Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03518112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*